Formulation and In Vitro Evaluation of Bilayer Tablets of Nebivolol Hydrochloride and Nateglinide for the Treatment of Diabetes and Hypertension

Table 15

In vitro drug release data of Nateglinide sustained release tablets (N1 to N13).

Time (hrs)

N1

N2

N3

N4

N5

N6

N7

N8

N9

N10

N11

N12

N13

0

0

0

0

0

0

0

0

0

0

0

0

0

0

1

18 ± 3.99

14 ± 3.45

16 ± 3.51

29 ± 3.68

19 ± 4.03

16 ± 4.02

15 ± 3.38

10 ± 3.37

9 ± 3.90

8 ± 3.25

12 ± 3.64

10 ± 3.31

10 ± 3.96

2

40 ± 3.46

38 ± 4.14

28 ± 4.07

38 ± 3.72

39 ± 3.72

32 ± 3.61

20 ± 3.64

18 ± 3.99

15 ± 3.68

13 ± 3.63

20 ± 3.36

18 ± 3.61

17 ± 3.64

3

56 ± 3.14

59 ± 3.78

49 ± 3.54

54 ± 3.58

48 ± 3.80

41 ± 3.94

31 ± 437

26 ± 3.42

26 ± 3.42

24 ± 4.01

31 ± 4.24

29 ± 3.64

30 ± 3.76

4

78 ± 4.44

72 ± 3.45

61 ± 3.92

79 ± 4.45

61 ± 4.19

59 ± 4.55

42 ± 4.11

37 ± 3.98

32 ± 4.20

30 ± 4.25

39 ± 3.81

37 ± 4.29

38 ± 3.22

5

85 ± 3.83

83 ± 4.42

75 ± 3.96

94 ± 3.83

80 ± 3.27

73 ± 3.93

53 ± 3.67

48 ± 3.71

39 ± 3.63

37 ± 3.45

47 ± 3.53

45 ± 4.23

47 ± 3.61

6

97 ± 4.56

90 ± 4.28

84 ± 3.52

95 ± 3.36

85 ± 4.19

61 ± 4.10

59 ± 4.45

47 ± 3.06

45 ± 3.23

54 ± 3.69

53 ± 3.98

54 ± 3.83

7

95 ± 4.01

90 ± 4.08

91 ± 3.40

69 ± 3.36

65 ± 3.23

53 ± 3.67

51 ± 3.64

62 ± 3.58

59 ± 3.87

60 ± 4.09

8

96 ± 3.81

98 ± 3.79

78 ± 3.44

78 ± 3.44

60 ± 3.27

58 ± 4.21

79 ± 4.34

70 ± 4.01

71 ± 3.56

9

97 ± 3.43

85 ± 3.87

75 ± 4.14

65 ± 3.82

88 ± 3.46

81 ± 3.97

82 ± 4.13

10

98 ± 3.30

81 ± 3.74

74 ± 4.30

98 ± 3.97

90 ± 3.64

96 ± 3.98

11

92 ± 3.48

80 ± 4.16

99 ± 4.15

12

96 ± 3.92

89 ± 4.43